Aside from ibrutinib, sufferers with M-CLL, devoid of TP53 aberrations and in good shape plenty of to tolerate FCR therapy, may still be fantastic candidates to the latter, While using the advantage being that this cure is usually accomplished in six months although ibrutinib has to be taken indefinitely. This selection will be significantly useful